Literature DB >> 3540951

Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

A M Mes-Masson, J McLaughlin, G Q Daley, M Paskind, O N Witte.   

Abstract

The Philadelphia chromosome, observed in greater than 90% of patients with chronic myelogenous leukemia, results from a reciprocal translocation between chromosomes 9 and 22. The translocation breakpoint on chromosome 9 occurs near the ABL gene and correlates with the production of a chronic myelogenous leukemia-specific 8.5-kilobase ABL-related mRNA species accompanied by a structurally altered ABL protein (P210c-abl). The N-terminal sequence of the protein is derived from the BCR gene on chromosome 22. We have isolated overlapping cDNA clones from the K-562 cell line corresponding to approximately 8.5 kilobases of mRNA and have sequenced 2550 nucleotides at the 5' end. Our results indicate that the 5' end of the 8.5-kilobase mRNA consists of greater than 400 nucleotides of noncoding sequence that are greater than 80% G + C rich. Based on our sequence analysis, we propose that initiation of translation occurs at nucleotide 471, such that the initial 927 amino acids of P210c-abl are derived from BCR sequences. Our cDNA clones thus define the complete coding sequences for the P210c-abl gene product.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3540951      PMCID: PMC387222          DOI: 10.1073/pnas.83.24.9768

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  A simple and very efficient method for generating cDNA libraries.

Authors:  U Gubler; B J Hoffman
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

3.  Selection of initiation sites by eucaryotic ribosomes: effect of inserting AUG triplets upstream from the coding sequence for preproinsulin.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

Review 4.  Casein kinases--multipotential protein kinases.

Authors:  G M Hathaway; J A Traugh
Journal:  Curr Top Cell Regul       Date:  1982

5.  Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1981-10-24       Impact factor: 16.971

6.  A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity.

Authors:  O N Witte; S Goff; N Rosenberg; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

7.  Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.

Authors:  S J Collins; I Kubonishi; I Miyoshi; M T Groudine
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

10.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

View more
  33 in total

1.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

2.  Unique organization of the human BCR gene promoter.

Authors:  Q S Zhu; N Heisterkamp; J Groffen
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

3.  Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.

Authors:  K Keegan; D E Johnson; L T Williams; M J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants.

Authors:  L Varticovski; G Q Daley; P Jackson; D Baltimore; L C Cantley
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

5.  Shifting paradigms: the seeds of oncogene addiction.

Authors:  Charles L Sawyers
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

6.  The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.

Authors:  G D Kruh; R Perego; T Miki; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation.

Authors:  A J Muller; O N Witte
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

8.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

9.  Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.

Authors:  B J Mayer; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

10.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.

Authors:  S S Clark; E Chen; M Fizzotti; O N Witte; V Malkovska
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.